ATE225177T1 - Verwendung von (+)mefloquine zur behandlung von malaria - Google Patents
Verwendung von (+)mefloquine zur behandlung von malariaInfo
- Publication number
- ATE225177T1 ATE225177T1 AT98910836T AT98910836T ATE225177T1 AT E225177 T1 ATE225177 T1 AT E225177T1 AT 98910836 T AT98910836 T AT 98910836T AT 98910836 T AT98910836 T AT 98910836T AT E225177 T1 ATE225177 T1 AT E225177T1
- Authority
- AT
- Austria
- Prior art keywords
- quinolinemethanol
- piperidinyl
- trifluoromethyl
- alpha
- bis
- Prior art date
Links
- 201000004792 malaria Diseases 0.000 title abstract 3
- XEEQGYMUWCZPDN-SWLSCSKDSA-N (+)-(11R,2'S)-erythro-mefloquine Chemical compound C([C@H]1[C@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-SWLSCSKDSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9704809.4A GB9704809D0 (en) | 1997-03-07 | 1997-03-07 | Chemical compounds |
| GBGB9722232.7A GB9722232D0 (en) | 1997-10-21 | 1997-10-21 | Chemical compounds |
| GBGB9724263.0A GB9724263D0 (en) | 1997-11-17 | 1997-11-17 | Chemical compounds |
| GBGB9724712.6A GB9724712D0 (en) | 1997-11-21 | 1997-11-21 | Chemical compounds |
| PCT/GB1998/000675 WO1998039003A1 (en) | 1997-03-07 | 1998-03-06 | Use of (+)mefloquine for the treatment of malaria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE225177T1 true ATE225177T1 (de) | 2002-10-15 |
Family
ID=27451612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98910836T ATE225177T1 (de) | 1997-03-07 | 1998-03-06 | Verwendung von (+)mefloquine zur behandlung von malaria |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6664397B1 (enExample) |
| EP (1) | EP0966285B1 (enExample) |
| JP (1) | JP4380800B2 (enExample) |
| AT (1) | ATE225177T1 (enExample) |
| AU (1) | AU730818B2 (enExample) |
| DE (1) | DE69808440T2 (enExample) |
| DK (1) | DK0966285T3 (enExample) |
| ES (1) | ES2185153T3 (enExample) |
| PT (1) | PT966285E (enExample) |
| WO (1) | WO1998039003A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0975345A1 (en) * | 1997-11-26 | 2000-02-02 | Cerebrus Pharmaceuticals Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
| GB0021776D0 (en) | 2000-09-05 | 2000-10-18 | Arakis Ltd | The treatment of inflammatory disorders |
| GB0406014D0 (en) * | 2004-03-17 | 2004-04-21 | Arakis Ltd | Pharmaceutical composition and use |
| US20070032480A1 (en) * | 2005-06-14 | 2007-02-08 | The Johns Hopkins University | Treatment of ischemia-induced arrhythmias |
| RU2008135762A (ru) * | 2006-02-16 | 2010-03-27 | Де МакЛин Хоспитал Корпорейшн (US) | Способы и композиции для лечения болезни паркинсона |
| US20110039888A1 (en) * | 2008-04-21 | 2011-02-17 | Coltart Don M | Asymmetric alpha functionalization and alpha, alpha bisfunctionalization of aldehydes and ketones |
| US8293783B2 (en) * | 2009-03-24 | 2012-10-23 | National University Of Singapore | Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (COPD) |
| US8716265B2 (en) | 2010-11-18 | 2014-05-06 | Jenrin Discovery, Inc. | 4-quinolinemethanols as anti-malarial agents |
| EP2487157A1 (en) | 2011-02-11 | 2012-08-15 | Université de Picardie Jules Verne | Enantioselective synthesis method of 4-aminoalcoholquinoline derivatives and the use |
| RU2015105407A (ru) * | 2012-08-09 | 2016-10-10 | Кэн-Файт Биофарма Лтд. | Лиганды аденозинового рецептора а3 для применения при лечении половой дисфункции |
| CN103304538B (zh) * | 2013-06-21 | 2014-12-24 | 中国人民解放军第四军医大学 | 右旋甲氟喹的合成 |
| CN107149601B (zh) * | 2017-05-25 | 2020-04-17 | 中国中医科学院中药研究所 | 青蒿素类化合物在制备治疗神经病理性疼痛和/或并发症的药物中的应用 |
| US11220482B2 (en) | 2017-11-03 | 2022-01-11 | Universite Amiens Picardie Jules Verne | Aminopyridinemethanol compounds and their use |
| CN110507646A (zh) * | 2019-09-12 | 2019-11-29 | 广州中医药大学(广州中医药研究院) | 青蒿素衍生物在制备抗焦虑症的药物或缓解焦虑症的食品中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| DE2940443A1 (de) | 1979-10-05 | 1981-04-16 | Basf Ag, 6700 Ludwigshafen | Verfahren zur herstellung von erythro-(alpha)-2-piperidyl-2,8-bis-(trifluormethyl)-4-chinolin-methanol |
| GB8322007D0 (en) | 1983-08-16 | 1983-09-21 | Wellcome Found | Pharmaceutical delivery system |
| US4769027A (en) | 1984-08-15 | 1988-09-06 | Burroughs Wellcome Co. | Delivery system |
-
1998
- 1998-03-06 DK DK98910836T patent/DK0966285T3/da active
- 1998-03-06 PT PT98910836T patent/PT966285E/pt unknown
- 1998-03-06 AT AT98910836T patent/ATE225177T1/de not_active IP Right Cessation
- 1998-03-06 US US09/380,353 patent/US6664397B1/en not_active Expired - Fee Related
- 1998-03-06 JP JP53828198A patent/JP4380800B2/ja not_active Expired - Lifetime
- 1998-03-06 AU AU65068/98A patent/AU730818B2/en not_active Ceased
- 1998-03-06 DE DE69808440T patent/DE69808440T2/de not_active Expired - Fee Related
- 1998-03-06 WO PCT/GB1998/000675 patent/WO1998039003A1/en not_active Ceased
- 1998-03-06 EP EP98910836A patent/EP0966285B1/en not_active Expired - Lifetime
- 1998-03-06 ES ES98910836T patent/ES2185153T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0966285B1 (en) | 2002-10-02 |
| EP0966285A1 (en) | 1999-12-29 |
| DK0966285T3 (da) | 2002-10-28 |
| JP4380800B2 (ja) | 2009-12-09 |
| HK1024631A1 (en) | 2000-10-20 |
| ES2185153T3 (es) | 2003-04-16 |
| AU6506898A (en) | 1998-09-22 |
| US6664397B1 (en) | 2003-12-16 |
| DE69808440T2 (de) | 2003-07-10 |
| PT966285E (pt) | 2002-12-31 |
| AU730818B2 (en) | 2001-03-15 |
| DE69808440D1 (de) | 2002-11-07 |
| JP2001526637A (ja) | 2001-12-18 |
| WO1998039003A1 (en) | 1998-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE225177T1 (de) | Verwendung von (+)mefloquine zur behandlung von malaria | |
| EA200101156A1 (ru) | ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ | |
| FI973163A0 (fi) | Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä | |
| EA200700232A1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| DK1223980T3 (da) | Anvendelse af CSF-1-inhibitorer | |
| ATE320803T1 (de) | Verfahren zur behandlung von alzheimerschen krankheit | |
| DK0668763T3 (da) | Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme | |
| SE9701144D0 (sv) | Novel compounds, their use and preparation | |
| DE69943107D1 (de) | Behandlung von autoimmunerkrankungen | |
| DK0998287T3 (da) | Anvendelse af levobupivacain | |
| ATE201597T1 (de) | Verabreichung von riluzol zur behandlung von neuro-aids | |
| ID24228A (id) | (+)norcisaprida yang berguna untuk gangguan tertular 5-ht3 dan 5-ht4 | |
| DE69841267D1 (de) | Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit | |
| DK1007055T3 (da) | Anvendelse af amifostin | |
| ATE319473T1 (de) | Melagatran zur behandlung von entzündungen | |
| DK1000046T3 (da) | Piperazinderivater, der er aktive på den nedre urinvejskanal | |
| AU1656997A (en) | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer | |
| DK1244438T3 (da) | Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde | |
| TW349864B (en) | Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders | |
| DE69729201D1 (de) | Sulfonfluoride zur behandlung von der alzheimerischen krankheit | |
| BG105984A (bg) | Използване на озанетант за приготвяне на лекарствени средства полезни за лечение на разстройства на настроението | |
| BR9708922A (pt) | Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso | |
| DE69910706D1 (de) | Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie | |
| CA2387394A1 (en) | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder | |
| DE69800906D1 (de) | Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0966285 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |